2. miRNA Deregulation in Prostate Cancer: An Overview
In cancers, aberrantly expressed miRNAs function as either tumor-suppressive or oncogenic miRNAs
[5]. The dysregulation of miRNAs, therefore, accounts for one of the mechanisms underlying the development and progression of PCa and other cancers
[11].
Let-7, as mentioned above, was first discovered in
C. elegans and was found to be downregulated in various cancers, and it acts as a tumor suppressor by targeting several oncogenes
[34]. Previous studies have shown that decreased levels of let-7 in lung cancer directly increased the expression of the oncogene
RAS. Conversely, restoring let-7 levels in hepatic and colon cancer restricts the growth and proliferation of cancerous cells
[35]. The downregulation of let-7a has been demonstrated in several studies. For example, Guanlin et al. showed a negative correlation between the expression levels of CC chemokine receptor 7 (CCR7) and let-7a in PCa. The inhibition of let-7a resulted in the upregulation of CCR7, thereby enhancing CCR7 binding to its ligands (CCRL19 and CCRL21) and triggering the activation of MAPK-mediated EMT signaling in PCa. This hyperactivation of CCR7/MAPK/EMT signaling (due to the downregulation of let-7a) further promotes PCa cell invasion
[36]. In castration-resistant prostate cancer (CRPC), let-7c is downregulated. Upon transfection of let-7c, cell growth and clonogenicity were inhibited in PCa
[37].
MiR-1 is known to be suppressed in many cancers, including PCa, hepatocarcinoma, chordoma, and esophageal squamous cell carcinoma
[38]. It has been shown that miR-1 is downregulated in PCa cells when compared to normal human prostate epithelial cells. MiR-1 is able to reduce cell viability and proliferation by targeting the c-Met/AKT/mTOR signaling pathway in PC-3 cells
[38]. The luciferase assay further confirmed
MET and
KRAS (encoding c-Met and K-Ras, respectively) to be direct targets of miR-1
[38][39][38,39]. The inhibition of miR-1 using a miR-1 antagomir promoted cell proliferation in PC-3 cells
[38]. In contrast, the overexpression of miR-1 inhibits cell proliferation, invasion, migration, and epithelial–mesenchymal transition (EMT) in PCa cells
[38][39][38,39] and also suppresses tumorigenesis in xenograft PCa mouse models
[39].
Studies have suggested that miR-29b and miR-30c play important roles in regulating cellular functions such as differentiation, proliferation, and apoptosis in cancers. RT-qPCR results have shown that the expression levels of miR-30c/-29b were reduced in PCa tissues compared to non-cancerous tissues. Additionally, a negative correlation was observed between miR-30c/-29b and cancer aggressiveness. Specifically, lower expression levels of miR-30c/-29b are correlated with more lymph node metastasis, more bone metastasis, and a higher Gleason score in PCa
[40]. A previous study revealed that miR-30c targets the 3′-UTR of
SRSF1 (encoding alternative splicing factor/splicing factor 2, ASF/SF2) and
E2F7 (encoding E2F Transcription Factor 7)
[41]. MiR-29b targets and negatively regulates
MCL1 and
AKT2, while AKT2 expression suppresses Bim1. It has been shown that the overexpression of miR-29 inhibits
AKT2, thereby upregulating Bim1 and enhancing Bim-1-mediated cell apoptosis in PCa
[42]. The downregulation of tumor-suppressive miR-29b was observed in various cancers, such as lung, breast, colon, gastric, and ovarian cancers, medulloblastoma, and multiple myeloma
[43][44][43,44].
MiR-34a and miR-99b are two important tumor-suppressive miRNAs in cancers, including PCa
[45][46][47][45,46,47]. MiR-34a belongs to the miR-34 family, along with two other miRNAs: miR-34b and miR-34c
[48]. The expression level of miR-34a is higher than that of miR-34b/c in most tissues
[49][50][49,50]. MiR-34a is a direct target of p53
[51] and is involved in p53-mediated apoptosis, cell cycle arrest, and senescence
[52]. Additionally, miR-34a functionally regulates the cell cycle, cell proliferation, senescence, migration, and invasion by targeting multiple genes, such as
CDK4/6,
E2F3,
MET,
BCL2,
SIRT1,
MYC,
NOTCH1, and
CD44 [48][53][48,53]. Previous studies have reported that miR-34a acts as a tumor suppressor and is downregulated in a wide range of cancers, such as PCa, glioma, medulloblastoma, laryngeal cancer, lung, breast cancer, ovarian cancer, bladder cancer, colon cancer, and liver cancer
[54][55][56][57][54,55,56,57]. The study by Fujita et al. showed that the expression of miR-34a was reduced in PCa specimens and cell lines when compared with their normal controls
[58].
Another tumor-suppressive miRNA, miR-99b, belongs to the miR-125a-let-7e cluster. MiR-99b-5p is frequently downregulated and was found to regulate differentiation, proliferation, invasion, and migration in PCa, cervical, breast, esophageal, gastric, and colon cancers
[59][60][61][62][63][64][59,60,61,62,63,64]. Members of miR-99 were downregulated in advanced PCa compared to the normal prostate epithelium. Through the luciferase reporter assay, three direct target genes were identified:
SMARCD1,
SMARCA5, and
MTOR. In addition, by increasing the levels of miR-99 family members, a reduced level of the androgen receptor (AR) was found in the C4-2 cell line. At both the mRNA and protein levels, miR-99 members reduced PSA expression
[60].
TheOur recent studies have also confirmed that miR-99b-5p negatively regulates the expression levels of mTOR
[45][65][45,65] and AR
[65] and blocks the nuclear translocation of AR and mTOR
[65]. The overexpression of miR-99b-5p resulted in the inhibition of cell proliferation/viability, the enhancement of cell apoptosis, and the sensitization of PCa, breast, colon, and lung cancer cells to docetaxel
[65].
MiR-99b-5p has been shown to be a tumor-suppressive miRNA in various cancers, including PCa
[66]. In PCa, a functional link between miR-133a-5p and
FUS/AR was revealed by Zheng et al. Specifically, miR-133a-5p directly targets the 3′-UTRs of
FUS and
AR and inhibits the expression of
FUS and
AR [67]. In addition, the overexpression of miR-133a resulted in a significant reduction in the cell viability of the PCa cell lines VCaP and LNCaP. Not only
FUS and
AR but also the downstream targets of AR, such as
IGF1R and
EGFR, were negatively regulated by miR-133a. Moreover, cell proliferation is enhanced upon the inhibition of miR-133a
[67]. In another study by Tang et al., miR-133a-3p was found to directly target
EGFR,
FGFR1,
IGF1R, and
MET in PCa cells. Due to the downregulation of miR-133a-3p, EGFR/PI3K/AKT signaling is upregulated in PCa
[68].
It has been indicated that miR-134-5p plays a critical role in suppressing human cancers
[69]. It affects various oncogenic signaling pathways, such as MAPK/ERK, Notch, and EGFR signaling, by targeting different genes within those pathways. When miR-134 is upregulated, it inhibits the expression of cyclin D/cyclin D2/CDK4, KRAS, EGFR, POGLUT1, and STAT5B proteins, resulting in a decrease in cell proliferation. Furthermore, miR-134 targets and inhibits
KRAS,
NANON,
HNF4A,
EGFR,
ITGB1, and
FOXM1, leading to the inhibition of tumor invasion and metastasis in PCa
[70]. In addition, Ngalame et al. demonstrated a negative correlation between miR-134 and
RAS oncogenes. The downregulation of miR-134 is associated with the activation of RAS/ERK and PI3K/PTEN/AKT signaling pathways in human prostate epithelial and stem cells
[71]. The study by Pelka et al. further revealed the downregulation of miR-134-5p in PCa vs. BPH and demonstrated a negative correlation between miR-134-5p expression levels and Gleason scores
[69].
MiR-205 serves a major function as a tumor-suppressive miRNA in cancers. MiR-205 is known to regulate cell proliferation, migration, and invasion by regulating E-cadherin through the targeting/inhibition of
ZEB1 and
ZEB2 [72]. In PCa, miR-205 is frequently downregulated and functions as a tumor-suppressive miRNA. It inhibits the expression of the androgen receptor (AR) and mitogen-activated protein kinase (MAPK). Similarly, miR-205 is downregulated and also functions as a tumor suppressor in other cancers, such as breast cancer, liver cancer, skin cancer, glioblastoma, pancreatic cancer, colorectal cancer, and renal cancer
[73].
MiR-221-5p is a miRNA demonstrating dual functional roles. Kiener et al. explored the tumor-suppressive role of miR-221-5p in PCa. The expression level of miR-221-5p was found to be downregulated in PCa vs. normal prostate tissue, as well as in metastasis vs. primary PCa
[74]. The overexpression of miR-221-5p in a PCa cell line decreased cell proliferation, migration, and colony formation. In contrast, the knockdown of miR-221-5p led to the opposite changes
[74]. MiR-221-5p has also been reported to target
SOCS1 and inhibit its expression at RNA and protein levels, subsequently suppressing Ras/Raf/MEK/ERK signaling cascades in PCa
[75]. Moreover, miR-221-5p targets
BMI1 and inhibits BMI protein expression, resulting in the inhibition of PCa proliferation
[76]. On the other hand, miR-221 has also been found to be upregulated in bone metastatic CRPC, suggesting its role as an oncogenic miRNA. Sun et al. identified
HECTD2 and
RAB1A as targets of miR-221. The overexpression of miR-221 inhibits
HECTD2 and
RAB1A expression, promoting androgen independency, AR reprogramming, and CRPC progression
[77].
Similar to miR-221-5p, miR-375-3p represents another miRNA that potentially exhibits dual functional roles. MiR-375 was found to be downregulated in PCa. It was found that miR-375 targets and inhibits
QKI5 in PCa, inhibiting QKI5-mediated gene expression in PCa
[78]. In addition, miR-375 targets/inhibits
CD44 and its splice variants. The downregulation of miR-375 was observed in androgen-independent PC-3 and DU-145
[79]. Abramovic and colleagues, however, reported that miR-375-3p is a potent PCa biomarker due to its oncogenic properties. They found that miR-375-3p was highly expressed in the blood plasma of males with PCa compared to benign prostatic hyperplasia (BPH) patients. It was also suggested to be a higher-performance diagnostic marker compared to PSA
[80].
MiR-21 has been found to be overexpressed in various types of cancers, including PCa and a wide range of other cancers
[81]. With its ability to promote cell proliferation/invasion and metastasis and inhibit apoptosis, miR-21 is known as an oncogenic miRNA
[82]. A previous report demonstrated that miR-21 is overexpressed in doxorubicin (DOX)-resistant PC-3 cells compared to the parental PC-3 cells.
PTEN was identified as a direct target of miR-21. The suppression of miR-21 resulted in the upregulation of PTEN and a significant reduction in p-glycoprotein (P-gp, an MDR protein), subsequently inhibiting PI3K/AKT signaling, reversing drug resistance, and enhancing apoptosis in DOX-resistant PC-3 cells
[83].
Studies have shown that miR-96-5p is significantly upregulated in PCa and various cancers, and it has a functional role linked to the tumor size, metastasis, and malignancy
[84]. In PCa, miR-96-5p has been shown to target tumor suppressor genes
FOXO1 and
MTSS1. The overexpression of miR-96-5p, therefore, promotes cell proliferation, colony formation, and invasion in PCa
[85]. It has also been reported that EGFR induces/activates miR-96-5p expression, which in turn targets and inhibits the tumor suppressor gene
ETV6 and consequently promotes PCa cell proliferation. In addition, miR-96-5p has been demonstrated to regulate autophagy by targeting
MTOR and
ATG7 in PCa under hypoxia
[69].
MiR-106b functions as an oncogene, and it is upregulated in various cancers, including PCa, breast cancer, lung cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma
[86]. MiR-106b target genes include
TEN,
AKT,
CNN1,
LARP4B,
RUNX3,
DAB2,
DLC1,
FOG2,
REST1,
FUT6,
ALEX1, and
BTG3
[86]. In the PCa cell line LNCaP, miR-106b directly targets and inhibits
CDKN1A (encoding p21), which leads to a G2/M cell cycle arrest. MiR-106b also regulates the expression of Ki67, MMP2, CD44, and Smad2 proteins in PCa cells
[87].
Another miRNA that displays oncogenic properties is miR-125b. It has been reported that PCa tumor growth is significantly increased when miR-125b is overexpressed in either intact or castrated male nude mice
[88]. Notably, one of the oncogenic mechanisms underlying PCa progression is mediated through the inhibition of the pro-apoptotic genes
TP53,
PUMA, and
BAK1 and their downstream signaling pathways by miR-125b. In contrast, the inhibition of miR-125b increases cell apoptosis in PCa cells
[88].
The oncogenic miRNA miR-141-3p is overexpressed in PCa cell lines and patient samples. It has been shown that the high-level expression of miR-141-3p promotes cell proliferation, 3D spheroid formation, tumorigenesis, stemness, and chemoresistance in PCa cell lines
[89]. In addition, miR-141 is involved in cell proliferation by targeting/inhibiting
PTEN,
BRD3, and
UBAP1, enhancing the activation of AKT and Rb/E2F signaling pathways in nasopharyngeal carcinoma
[89].
The deregulation of miRNAs is one of the mechanisms conferring drug resistance in cancers, thereby leading to therapeutic failures. For example, the upregulation of miR-145 has been correlated with chemoresistance in PCa and other cancers
[90]. A previous study further showed that the upregulation of miR-145 resulted in the downregulation of P-gp (P-glycoprotein) and pRb (retinoblastoma protein) by targeting and inhibiting
SP1 (encoding specific protein 1) and
CDK6 (encoding cyclin-dependent kinase 6)
[90].
MiR-182 was also found to be upregulated in PCa. The overexpression of miR-182 results in increased cell proliferation through the targeting/regulation of the expression of
NDRG1,
GNA13, and
BRCA1 in PCa. The study by Bai et al. showed that miR-182 acts as an oncogene and is upregulated in breast cancer, ovarian cancer, pancreatic cancer, and colorectal cancer. In PCa, miR-182 directly targets the 3′-UTR of
ST6GALNAC5 [91].
MiR-200c, belonging to the miR-200 family, is known to play a role in promoting tumor progression in PCa and various cancers
[92]. In the study of Lin et al., miR-200c was highly expressed in PCa cell lines compared to normal prostate cells
[93]. Similarly, miR-200c is highly expressed in ovarian, endometrial, and esophageal cancers, consequently enhancing tumor growth and promoting chemoresistance
[92]. However, various studies have expressed contrasting roles of miR-200c. For instance, it was found that miR-200c negatively regulates the expression of ZEB1 and vimentin, displaying an inhibitory effect on EMT-mediated cell proliferation, invasion, and migration in PCa
[94]. Moreover, miR-200c acts as a tumor suppressor by inhibiting
FOXF2 and
BMI1 expression, consequently inhibiting cancer invasion and migration
[95].
It was also found that miR-222 targets and negatively regulates
CDKN1B (encoding p27kip1), a negative regulator of cell cycle progression in PCa and many other cancers
[96]. The expression levels of miR-222 were found to be negatively correlated with PCa aggressiveness. Additionally, the overexpression of miR-222 resulted in increased cell proliferation in vitro and tumorigenicity in vivo
[97]. Similar to PCa, the expression level of miR-222 was significantly associated with the tumor grade in uterine cancer
[98] and tamoxifen resistance in breast cancer
[99].